How long does a knee replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
16 02 2019
Historique:
received: 24 08 2018
revised: 01 10 2018
accepted: 04 10 2018
entrez: 21 2 2019
pubmed: 21 2 2019
medline: 10 4 2019
Statut: ppublish

Résumé

Knee replacements are the mainstay of treatment for end-stage osteoarthritis and are effective. Given time, all knee replacements will fail and knowing when this failure might happen is important. We aimed to establish how long a knee replacement lasts. In this systematic review and meta-analysis, we searched MEDLINE and Embase for case series and cohort studies published from database inception until July 21, 2018. Articles reporting 15 year or greater survival of primary total knee replacement (TKR), unicondylar knee replacement (UKR), and patellofemoral replacements in patients with osteoarthritis were included. Articles that reviewed specifically complex primary surgeries or revisions were excluded. Survival and implant data were extracted, with all-cause survival of the knee replacement construct being the primary outcome. We also reviewed national joint replacement registry reports and extracted the data to be analysed separately. In the meta-analysis, we weighted each series and calculated a pooled survival estimate for each data source at 15 years, 20 years, and 25 years, using a fixed-effects model. This study is registered with PROSPERO, number CRD42018105188. From 4363 references found by our initial search, we identified 33 case series in 30 eligible articles, which reported all-cause survival for 6490 TKRs (26 case series) and 742 UKRs (seven case series). No case series reporting on patellofemoral replacements met our inclusion criteria, and no case series reported 25 year survival for TKR. The estimated 25 year survival for UKR (based on one case series) was 72·0% (95% CI 58·0-95·0). Registries contributed 299 291 TKRs (47 series) and 7714 UKRs (five series). The pooled registry 25 year survival of TKRs (14 registries) was 82·3% (95% CI 81·3-83·2) and of UKRs (four registries) was 69·8% (67·6-72·1). Our pooled registry data, which we believe to be more accurate than the case series data, shows that approximately 82% of TKRs last 25 years and 70% of UKRs last 25 years. These findings will be of use to patients and health-care providers; further information is required to predict exactly how long specific knee replacements will last. The National Joint Registry for England, Wales, Northern Ireland, and Isle of Man and the Royal College of Surgeons of England.

Sections du résumé

BACKGROUND
Knee replacements are the mainstay of treatment for end-stage osteoarthritis and are effective. Given time, all knee replacements will fail and knowing when this failure might happen is important. We aimed to establish how long a knee replacement lasts.
METHODS
In this systematic review and meta-analysis, we searched MEDLINE and Embase for case series and cohort studies published from database inception until July 21, 2018. Articles reporting 15 year or greater survival of primary total knee replacement (TKR), unicondylar knee replacement (UKR), and patellofemoral replacements in patients with osteoarthritis were included. Articles that reviewed specifically complex primary surgeries or revisions were excluded. Survival and implant data were extracted, with all-cause survival of the knee replacement construct being the primary outcome. We also reviewed national joint replacement registry reports and extracted the data to be analysed separately. In the meta-analysis, we weighted each series and calculated a pooled survival estimate for each data source at 15 years, 20 years, and 25 years, using a fixed-effects model. This study is registered with PROSPERO, number CRD42018105188.
FINDINGS
From 4363 references found by our initial search, we identified 33 case series in 30 eligible articles, which reported all-cause survival for 6490 TKRs (26 case series) and 742 UKRs (seven case series). No case series reporting on patellofemoral replacements met our inclusion criteria, and no case series reported 25 year survival for TKR. The estimated 25 year survival for UKR (based on one case series) was 72·0% (95% CI 58·0-95·0). Registries contributed 299 291 TKRs (47 series) and 7714 UKRs (five series). The pooled registry 25 year survival of TKRs (14 registries) was 82·3% (95% CI 81·3-83·2) and of UKRs (four registries) was 69·8% (67·6-72·1).
INTERPRETATION
Our pooled registry data, which we believe to be more accurate than the case series data, shows that approximately 82% of TKRs last 25 years and 70% of UKRs last 25 years. These findings will be of use to patients and health-care providers; further information is required to predict exactly how long specific knee replacements will last.
FUNDING
The National Joint Registry for England, Wales, Northern Ireland, and Isle of Man and the Royal College of Surgeons of England.

Identifiants

pubmed: 30782341
pii: S0140-6736(18)32531-5
doi: 10.1016/S0140-6736(18)32531-5
pmc: PMC6381229
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

655-663

Subventions

Organisme : Medical Research Council
ID : MR/L01226X/1
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

BMJ Open. 2012 Feb 22;2(1):e000435
pubmed: 22357571
Knee. 2017 Mar;24(2):447-453
pubmed: 28143683
J Bone Joint Surg Am. 2005 Mar;87(3):598-603
pubmed: 15741628
J Arthroplasty. 2018 Aug;33(8):2524-2529
pubmed: 29685710
Lancet. 2017 Apr 8;389(10077):1424-1430
pubmed: 28209371
ANZ J Surg. 2003 Sep;73(9):712-6
pubmed: 12956787
Clin Orthop Relat Res. 1999 Oct;(367):210-5
pubmed: 10546617
BMJ Open. 2017 Nov 3;7(11):e018105
pubmed: 29101145
Lancet. 2012 Apr 7;379(9823):1331-40
pubmed: 22398175
Int Orthop. 2017 Jun;41(6):1155-1162
pubmed: 28326442
Knee. 2017 Jun;24(3):497-507
pubmed: 27923627
Acta Orthop. 2018 Jun;89(3):256-258
pubmed: 29521152
J Bone Joint Surg Br. 2012 Aug;94(8):1067-70
pubmed: 22844047
Clin Orthop Relat Res. 2013 Jan;471(1):102-8
pubmed: 22895691
J Arthroplasty. 2017 Jun;32(6):1874-1879
pubmed: 28209274
Clin Orthop Relat Res. 2014 May;472(5):1496-501
pubmed: 24249531
Clin Orthop Relat Res. 2018 Jan;476(1):6-15
pubmed: 29389753
J Arthroplasty. 2010 Feb;25(2):173-8
pubmed: 19195825
Clin Orthop Relat Res. 2015 Jan;473(1):135-40
pubmed: 25082622
J Bone Joint Surg Am. 2010 Jul 7;92(7):1635-9
pubmed: 20595570
Int Orthop. 2014 Feb;38(2):305-11
pubmed: 24382665
Clin Orthop Relat Res. 2006 Nov;452:28-34
pubmed: 16936585
N Z Med J. 2003 Oct 10;116(1183):U627
pubmed: 14581941
Osteoarthritis Cartilage. 2013 Feb;21(2):263-8
pubmed: 23220555
Lancet. 2019 Feb 16;393(10172):647-654
pubmed: 30782340
J Bone Joint Surg Am. 2013 May 15;95(10):905-9
pubmed: 23677357
J Arthroplasty. 2017 Jul;32(7):2161-2166
pubmed: 28285899
Acta Orthop Belg. 2009 Apr;75(2):225-33
pubmed: 19492562
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
J Bone Joint Surg Br. 2009 Jan;91(1):52-7
pubmed: 19092004
Open Orthop J. 2009 May 18;3:36-9
pubmed: 19572035
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
J Bone Joint Surg Am. 2005 Sep;87(9):1995-8
pubmed: 16140814
Clin Orthop Relat Res. 2013 Jan;471(1):109-17
pubmed: 22669547
Clin Orthop Relat Res. 2005 Nov;440:27-37
pubmed: 16239780
Clin Orthop Relat Res. 2012 Jan;470(1):61-8
pubmed: 21732024
Bone Joint J. 2015 Feb;97-B(2):197-201
pubmed: 25628282
Clin Orthop Relat Res. 2015 Jul;473(7):2327-33
pubmed: 25721577

Auteurs

Jonathan T Evans (JT)

Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Southmead Hospital, Bristol, UK. Electronic address: j.t.evans@bristol.ac.uk.

Robert W Walker (RW)

Department of Trauma and Orthopaedics, Torbay and South Devon NHS Foundation Trust, Torquay, UK.

Jonathan P Evans (JP)

Health and Policy Research Group, University of Exeter, Exeter, UK.

Ashley W Blom (AW)

Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Southmead Hospital, Bristol, UK; National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals, Bristol NHS Foundation Trust, University of Bristol, Bristol, UK.

Adrian Sayers (A)

Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Southmead Hospital, Bristol, UK.

Michael R Whitehouse (MR)

Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Southmead Hospital, Bristol, UK; National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals, Bristol NHS Foundation Trust, University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH